SLXN - Silexion Therapeutics Corp

QQQ $ 604.92 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 665.28 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.28 $ -7.46 (-1.88 %)

Previous Close

$ 3.52

Open

$ 3.52

Bid

$ 3.56 x 308

Ask

$ 3.87 x 3

Day's Range

$ 3.43 - $ 3.61

52 Week Range

$ 3.25 - $ 63.45

Volume

61,618

Average Volume

Market Cap

2.04M

Beta (5Y Monthly)

$ 3.28

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-18-2025	12-31-2024	10-K
4	11-14-2024	09-30-2024	10-Q
5	08-29-2024	06-30-2024	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Silexion Therapeutics Says SIL204 Demonstr...
09/30/2025 12:41:41

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, ...

Silexion Therapeutics Files For Mixed Shel...
09/26/2025 20:34:02

- SEC Filing

Silexion Therapeutics Regains Nasdaq Compl...
09/25/2025 12:46:37

12 Health Care Stocks Moving In Friday's I...
09/12/2025 17:06:17

silexion-therapeutics-shares-surge-on-positive-preclinical-pancreatic-cancer-data

Silexion Therapeutics Shares Surge On Posi...
09/11/2025 17:26:25

Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic canc...

Silexion Therapeutics Prices $6M Public Of...
09/11/2025 13:18:12

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech ...

12 Health Care Stocks Moving In Thursday's...
09/11/2025 12:10:10

Market-Moving News for September 11th
09/11/2025 11:26:37

SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Tra...

Silexion Highlights Preclinical Data Of SI...
09/11/2025 11:07:35

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tu...

Silexion's SIL204 Reaches All Major Sites ...
09/11/2025 11:01:56

Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies ...

12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 17:06:26

Silexion Therapeutics Selects A Contract R...
09/04/2025 13:28:42

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL20...

CORRECTION: Silexion Therapeutics Q2 EPS $...
08/12/2025 21:59:53

Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(4.32) per share which missed the analyst consensus estimate ...

12 Health Care Stocks Moving In Monday's P...
08/11/2025 12:08:21

crude-oil-down-2-amazon-shares-tumble-after-q2-results

Crude Oil Down 2%; Amazon Shares Tumble Af...
08/01/2025 17:44:51

12 Health Care Stocks Moving In Friday's I...
08/01/2025 17:07:08

Nasdaq Dips Over 2%; Apple Earnings Top Views
08/01/2025 14:19:23

Reported Earlier, Silexion Therapeutics An...
08/01/2025 07:16:47

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purch...

why-is-silexion-therapeutics-stock-trading-higher-on-thursday

Why Is Silexion Therapeutics Stock Trading...
07/31/2025 19:14:14

Silexion's SIL204 showed strong KRAS-targeted inhibition across pancreatic, colorectal, and lung cancer cells, supporting i...

Silexion Therapeutics Shares Resume Trade ...
07/31/2025 14:23:31